{"success":true,"data":{"pressRelease":{"id":"9771","rtpr_id":"nGNX6tPmqH","ticker":"CRNX","exchange":"NASDAQ","all_tickers":["CRNX"],"title":"Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults","author":"Globe Newswire","published_at":"2026-04-27T21:13:07.946Z","article_body":"PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly\nin the European Union\n\nApproval based on strength of data from two pivotal Phase 3 studies studying\nPALSONIFY in both medical naïve and previously treated patients with\nacromegaly\n\nCrinetics’ first regulatory approval outside of the U.S., with first launch\nplanned for Germany and Austria\n\nSAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.\n(https://www.globenewswire.com/Tracker?data=tdgR94TFww1oMph_LP9n-JcxIXiXjH-uEKNDMM2hlSzyGtlt60LIvOQ3lUKWLK59Av2Df3N4VMm2sPXzFmVtzsSjoxFsuegvtfR9sC5Ivg8=)\n(Nasdaq: CRNX) today announced that the European Commission (EC) has approved\nPALSONIFY(®) (paltusotine), the first once-daily, oral, selectively-targeted\nsomatostatin receptor type 2 nonpeptide agonist, for the treatment of adult\npatients with acromegaly.\n\n“The European Commission’s decision to approve Palsonify reflects the\nstrength of the clinical data and marks a pivotal step toward bringing this\nimportant therapy to even more people living with acromegaly,” said Scott\nStruthers, Ph.D., Founder and Chief Executive Officer of Crinetics. “This\napproval represents another exciting milestone for Palsonify as it accelerates\nto become the new standard in acromegaly care in the U.S., and soon abroad.\nThis is also a notable achievement for Crinetics in pursuit of our vision to\nbecome the global leader in endocrinology.”\n\nThe EC approval is supported by positive results from the pivotal data from\nthe PATHFNDR-1\n(https://www.globenewswire.com/Tracker?data=t0ghsKOaNqJfPSQH7SUpqVhDhbPAg5UHMy9q0_OxdgeXH52gxKEHrAYf7ljBntmzBClO0J946iRtZG3MWbqs7rVBlwqPCzanWoWBt4Jk4tzDnnooqff9o-0KGwP1aMxdzP9oe1TJpOfk1gYawkE94CepCX7A3WkFGKxulCdNBxk3yN-7ZguhlCT05QJVSwQwJngUetNgEGcOO72CJrj8iki3TRbsXR4WF1HPXkzIf8g=) and PATHFNDR-2\n(https://www.globenewswire.com/Tracker?data=t0ghsKOaNqJfPSQH7SUpqa33Aq41aMGt-sV-PaMcOZRlo3hFIXQg6eAV-MvDKJsZPhJ7UYQhQulVzCjxW54W11yWrMv29Mo83R_PqoFlRz4p_WOak1cOyxJaJjf7c_LXhRvKjbln0Bef0LzBPQbAo2T4FyICv8jEb4bbSIR-LgnHkJrQMYU6PfeXjXxdJlGqvJ9WLQ6Vu8TIIcIK_AW052WNBPV_zCas8oYd_n2ew7h4zMIgFeYgt6sFg_iNg-2fE7IYyWuBb8u3YnvvuBo3FA==)\nPhase 3 trials, which evaluated PALSONIFY’s safety and efficacy in\npreviously treated and medically untreated adults with acromegaly. Across both\ntrials, PALSONIFY consistently demonstrated rapid onset, reliable biochemical\ncontrol, and sustained efficacy. PALSONIFY also has Orphan Drug Designation in\nthe EU.\n\nParticipants also reported significant reductions in signs and symptoms\nassociated with acromegaly – including headaches, joint pain, sweating,\nfatigue, weakness, swelling, and/or numbness/tingling – as measured by the\nAcromegaly Symptom Diary (ASD), a validated patient-reported outcome tool\ndeveloped to capture the symptoms that matter to people living with\nacromegaly.\n\nTreatment with PALSONIFY was generally well-tolerated, with no serious adverse\nevents reported in the randomized controlled portion of the trial. The most\nfrequently reported adverse reactions with paltusotine were diarrhea,\nabdominal pain, nausea, and abdominal discomfort.\n\nThe approval by the EC is valid in all 27 member states of the EU and three\nEuropean Economic Area (EEA) countries. Crinetics is currently planning\ninitial commercialization efforts in Germany and Austria.\n\nPALSONIFY is approved by the U.S. Food and Drug Administration (FDA) for the\nfirst-line treatment of adults with acromegaly who had an inadequate response\nto surgery and/or for whom surgery is not an option. Crinetics is also in\npartnership with Sanwa Kagaku Kenkyusho Co., Ltd (SKK) to develop and\ncommercialize PALSONIFY for acromegaly in Japan, where the Ministry of Health,\nLabour and Welfare recently granted an orphan drug designation. SKK recently\nsubmitted a new drug application (NDA) in Japan for paltusotine for the\ntreatment of acromegaly. In Brazil, Crinetics recently submitted a Marketing\nAuthorization Application (MAA) to Brazil’s National Health Surveillance\nAgency (ANVISA) for PALSONIFY for the proposed treatment of acromegaly in\nadults.\n\nAbout PALSONIFY(®) (Paltusotine)\nPALSONIFY, a selectively-targeted somatostatin receptor type 2 (SST2)\nnonpeptide agonist, is the first and only once-daily, oral therapy approved\nfor the treatment of adults with acromegaly who had an inadequate response to\nsurgery and/or for whom surgery is not an option. In Phase 3 studies,\nonce-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in\npatients with acromegaly who were switched from monthly injectable medications\n(PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in\nmedically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary\nbiomarker endocrinologists use to manage acromegaly patients. Paltusotine is\nalso in Phase 3 clinical development for carcinoid syndrome associated with\nneuroendocrine tumors (CAREFNDR). Results from a Phase 2 study in carcinoid\nsyndrome demonstrated rapid and sustained reductions in flushing episodes and\nbowel movement frequency, which are the most common symptoms of carcinoid\nsyndrome.\n\nPALSONIFY is approved in the U.S. for the first-line treatment of adults with\nacromegaly who had an inadequate response to surgery and/or for whom surgery\nis not an option. It is also approved for use in the EU for the medical\ntreatment of adult patients with acromegaly.\n\nImportant Safety Information \nThe full European Summary of Product Characteristics (SmPC) for PALSONIFY will\nbe available on the European Medicines Agency website at www.ema.europa.eu.\n\nAbout Crinetics Pharmaceuticals\nCrinetics Pharmaceuticals is a global pharmaceutical company committed to\ntransforming the treatment of endocrine diseases and endocrine-related tumors\nthrough science rooted in patient needs. Crinetics is focused on discovering,\ndeveloping, and commercializing novel therapies, with a core expertise in\ntargeting G-protein coupled receptors (GPCRs) with small molecules that have\nspecifically tailored pharmacology and properties.\n\nCrinetics’ lead product, PALSONIFY(®) (paltusotine), is the first\nonce-daily, oral treatment approved by healthcare regulatory authorities in\nU.S. and European Union for the treatment of adults with acromegaly.\nPaltusotine is also in clinical development for carcinoid syndrome associated\nwith neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed\nprograms includes late-stage investigational candidate atumelnant, which is\ncurrently in development for congenital adrenal hyperplasia and ACTH-dependent\nCushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that\nis being developed to treat SST2 expressing neuroendocrine tumors and other\nSST2 expressing solid tumors. Additional discovery programs address a variety\nof endocrine conditions such as neuroendocrine tumors, Graves’ disease\n(including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye\ndisease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity,\nand GPCR-targeted oncology indications. Crinetics is headquartered in San\nDiego, with European commercialization operations based in Zug, Switzerland.\nPlease visit www.crinetics.com for more information.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. All statements other than\nstatements of historical facts contained in this press release are\nforward-looking statements, including statements regarding the plans and\ntimelines for Crinetics, its affiliates or license partners to develop and\ncommercialize PALSONIFY for the treatment of acromegaly in Brazil or Japan,\nfor the clinical development of atumelnant and CRN09682 or for paltusotine for\nthe treatment of carcinoid syndrome; or the potential for our discovery\nprograms or development candidates to transition to clinical development. In\nsome cases, you can identify forward-looking statements by terms such as\n“may,” “will,” “should,” “expect,” “plan,”\n“anticipate,” “could,” “intend,” “target,” “project,”\n“contemplates,” “believes,” “estimates,” “predicts,”\n“potential,” “upcoming” or “continue” or the negative of these\nterms or other similar expressions. These forward-looking statements speak\nonly as of the date of this press release and are subject to a number of\nrisks, uncertainties and assumptions, including, without limitation, we may\nnot be able to obtain, maintain and enforce our patents and other intellectual\nproperty rights, and it may be prohibitively difficult or costly to protect\nsuch rights; geopolitical events may disrupt Crinetics’ business and that of\nthe third parties on which it depends, including delaying or otherwise\ndisrupting clinical studies and preclinical studies, manufacturing and supply\nchain, or impairing employee productivity; unexpected adverse side effects,\ncomplications and/or drug interactions or inadequate efficacy of the\nCompany’s product candidates that may limit their development, regulatory\napproval and/or commercialization; the Company’s dependence on third parties\nin connection with product manufacturing, research and preclinical and\nclinical testing; regulatory developments or political changes, including\npolicies related to pricing and pharmaceutical drug reimbursement, in the\nUnited States and foreign countries; the timing and outcome of research,\ndevelopment and regulatory review is uncertain, and Crinetics’ drug\ncandidates may not advance in development or be approved for marketing;\nCrinetics may use its capital resources sooner than expected or our cash burn\nrate may accelerate; any future impacts to our business resulting from\ngeopolitical developments outside our control; and the other risks and\nuncertainties described in the Company’s periodic filings with the\nSecurities and Exchange Commission (SEC). The events and circumstances\nreflected in the company’s forward-looking statements may not be achieved or\noccur and actual results could differ materially from those projected in the\nforward-looking statements. Additional information on risks facing Crinetics\ncan be found under the heading “Risk Factors” in Crinetics’ periodic\nfilings with the SEC, including its annual report on Form 10-K for the year\nended December 31, 2025. You are cautioned not to place undue reliance on\nthese forward-looking statements, which speak only as of the date hereof.\nExcept as required by applicable law, Crinetics does not plan to publicly\nupdate or revise any forward-looking statements contained herein, whether as a\nresult of any new information, future events, changed circumstances or\notherwise.\n\nInvestors:\nGayathri Diwakar\nHead of Investor Relations\ngdiwakar@crinetics.com\n(858) 345-6340\n\nMedia:\nNatalie Badillo\nHead of Corporate Communications\nnbadillo@crinetics.com\n(858) 345-6075\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ff5e7cfa-b9fb-4679-8bf3-6e9d25207b83)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX6tPmqH","title":"Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults","author":"Globe Newswire","ticker":"CRNX","created":"2026-04-27T21:13:07.946Z","tickers":["CRNX"],"exchange":"NASDAQ","article_body":"PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly\nin the European Union\n\nApproval based on strength of data from two pivotal Phase 3 studies studying\nPALSONIFY in both medical naïve and previously treated patients with\nacromegaly\n\nCrinetics’ first regulatory approval outside of the U.S., with first launch\nplanned for Germany and Austria\n\nSAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc.\n(https://www.globenewswire.com/Tracker?data=tdgR94TFww1oMph_LP9n-JcxIXiXjH-uEKNDMM2hlSzyGtlt60LIvOQ3lUKWLK59Av2Df3N4VMm2sPXzFmVtzsSjoxFsuegvtfR9sC5Ivg8=)\n(Nasdaq: CRNX) today announced that the European Commission (EC) has approved\nPALSONIFY(®) (paltusotine), the first once-daily, oral, selectively-targeted\nsomatostatin receptor type 2 nonpeptide agonist, for the treatment of adult\npatients with acromegaly.\n\n“The European Commission’s decision to approve Palsonify reflects the\nstrength of the clinical data and marks a pivotal step toward bringing this\nimportant therapy to even more people living with acromegaly,” said Scott\nStruthers, Ph.D., Founder and Chief Executive Officer of Crinetics. “This\napproval represents another exciting milestone for Palsonify as it accelerates\nto become the new standard in acromegaly care in the U.S., and soon abroad.\nThis is also a notable achievement for Crinetics in pursuit of our vision to\nbecome the global leader in endocrinology.”\n\nThe EC approval is supported by positive results from the pivotal data from\nthe PATHFNDR-1\n(https://www.globenewswire.com/Tracker?data=t0ghsKOaNqJfPSQH7SUpqVhDhbPAg5UHMy9q0_OxdgeXH52gxKEHrAYf7ljBntmzBClO0J946iRtZG3MWbqs7rVBlwqPCzanWoWBt4Jk4tzDnnooqff9o-0KGwP1aMxdzP9oe1TJpOfk1gYawkE94CepCX7A3WkFGKxulCdNBxk3yN-7ZguhlCT05QJVSwQwJngUetNgEGcOO72CJrj8iki3TRbsXR4WF1HPXkzIf8g=) and PATHFNDR-2\n(https://www.globenewswire.com/Tracker?data=t0ghsKOaNqJfPSQH7SUpqa33Aq41aMGt-sV-PaMcOZRlo3hFIXQg6eAV-MvDKJsZPhJ7UYQhQulVzCjxW54W11yWrMv29Mo83R_PqoFlRz4p_WOak1cOyxJaJjf7c_LXhRvKjbln0Bef0LzBPQbAo2T4FyICv8jEb4bbSIR-LgnHkJrQMYU6PfeXjXxdJlGqvJ9WLQ6Vu8TIIcIK_AW052WNBPV_zCas8oYd_n2ew7h4zMIgFeYgt6sFg_iNg-2fE7IYyWuBb8u3YnvvuBo3FA==)\nPhase 3 trials, which evaluated PALSONIFY’s safety and efficacy in\npreviously treated and medically untreated adults with acromegaly. Across both\ntrials, PALSONIFY consistently demonstrated rapid onset, reliable biochemical\ncontrol, and sustained efficacy. PALSONIFY also has Orphan Drug Designation in\nthe EU.\n\nParticipants also reported significant reductions in signs and symptoms\nassociated with acromegaly – including headaches, joint pain, sweating,\nfatigue, weakness, swelling, and/or numbness/tingling – as measured by the\nAcromegaly Symptom Diary (ASD), a validated patient-reported outcome tool\ndeveloped to capture the symptoms that matter to people living with\nacromegaly.\n\nTreatment with PALSONIFY was generally well-tolerated, with no serious adverse\nevents reported in the randomized controlled portion of the trial. The most\nfrequently reported adverse reactions with paltusotine were diarrhea,\nabdominal pain, nausea, and abdominal discomfort.\n\nThe approval by the EC is valid in all 27 member states of the EU and three\nEuropean Economic Area (EEA) countries. Crinetics is currently planning\ninitial commercialization efforts in Germany and Austria.\n\nPALSONIFY is approved by the U.S. Food and Drug Administration (FDA) for the\nfirst-line treatment of adults with acromegaly who had an inadequate response\nto surgery and/or for whom surgery is not an option. Crinetics is also in\npartnership with Sanwa Kagaku Kenkyusho Co., Ltd (SKK) to develop and\ncommercialize PALSONIFY for acromegaly in Japan, where the Ministry of Health,\nLabour and Welfare recently granted an orphan drug designation. SKK recently\nsubmitted a new drug application (NDA) in Japan for paltusotine for the\ntreatment of acromegaly. In Brazil, Crinetics recently submitted a Marketing\nAuthorization Application (MAA) to Brazil’s National Health Surveillance\nAgency (ANVISA) for PALSONIFY for the proposed treatment of acromegaly in\nadults.\n\nAbout PALSONIFY(®) (Paltusotine)\nPALSONIFY, a selectively-targeted somatostatin receptor type 2 (SST2)\nnonpeptide agonist, is the first and only once-daily, oral therapy approved\nfor the treatment of adults with acromegaly who had an inadequate response to\nsurgery and/or for whom surgery is not an option. In Phase 3 studies,\nonce-daily, oral PALSONIFY maintained IGF-1 levels and symptom control in\npatients with acromegaly who were switched from monthly injectable medications\n(PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in\nmedically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary\nbiomarker endocrinologists use to manage acromegaly patients. Paltusotine is\nalso in Phase 3 clinical development for carcinoid syndrome associated with\nneuroendocrine tumors (CAREFNDR). Results from a Phase 2 study in carcinoid\nsyndrome demonstrated rapid and sustained reductions in flushing episodes and\nbowel movement frequency, which are the most common symptoms of carcinoid\nsyndrome.\n\nPALSONIFY is approved in the U.S. for the first-line treatment of adults with\nacromegaly who had an inadequate response to surgery and/or for whom surgery\nis not an option. It is also approved for use in the EU for the medical\ntreatment of adult patients with acromegaly.\n\nImportant Safety Information \nThe full European Summary of Product Characteristics (SmPC) for PALSONIFY will\nbe available on the European Medicines Agency website at www.ema.europa.eu.\n\nAbout Crinetics Pharmaceuticals\nCrinetics Pharmaceuticals is a global pharmaceutical company committed to\ntransforming the treatment of endocrine diseases and endocrine-related tumors\nthrough science rooted in patient needs. Crinetics is focused on discovering,\ndeveloping, and commercializing novel therapies, with a core expertise in\ntargeting G-protein coupled receptors (GPCRs) with small molecules that have\nspecifically tailored pharmacology and properties.\n\nCrinetics’ lead product, PALSONIFY(®) (paltusotine), is the first\nonce-daily, oral treatment approved by healthcare regulatory authorities in\nU.S. and European Union for the treatment of adults with acromegaly.\nPaltusotine is also in clinical development for carcinoid syndrome associated\nwith neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed\nprograms includes late-stage investigational candidate atumelnant, which is\ncurrently in development for congenital adrenal hyperplasia and ACTH-dependent\nCushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that\nis being developed to treat SST2 expressing neuroendocrine tumors and other\nSST2 expressing solid tumors. Additional discovery programs address a variety\nof endocrine conditions such as neuroendocrine tumors, Graves’ disease\n(including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye\ndisease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity,\nand GPCR-targeted oncology indications. Crinetics is headquartered in San\nDiego, with European commercialization operations based in Zug, Switzerland.\nPlease visit www.crinetics.com for more information.\n\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended. All statements other than\nstatements of historical facts contained in this press release are\nforward-looking statements, including statements regarding the plans and\ntimelines for Crinetics, its affiliates or license partners to develop and\ncommercialize PALSONIFY for the treatment of acromegaly in Brazil or Japan,\nfor the clinical development of atumelnant and CRN09682 or for paltusotine for\nthe treatment of carcinoid syndrome; or the potential for our discovery\nprograms or development candidates to transition to clinical development. In\nsome cases, you can identify forward-looking statements by terms such as\n“may,” “will,” “should,” “expect,” “plan,”\n“anticipate,” “could,” “intend,” “target,” “project,”\n“contemplates,” “believes,” “estimates,” “predicts,”\n“potential,” “upcoming” or “continue” or the negative of these\nterms or other similar expressions. These forward-looking statements speak\nonly as of the date of this press release and are subject to a number of\nrisks, uncertainties and assumptions, including, without limitation, we may\nnot be able to obtain, maintain and enforce our patents and other intellectual\nproperty rights, and it may be prohibitively difficult or costly to protect\nsuch rights; geopolitical events may disrupt Crinetics’ business and that of\nthe third parties on which it depends, including delaying or otherwise\ndisrupting clinical studies and preclinical studies, manufacturing and supply\nchain, or impairing employee productivity; unexpected adverse side effects,\ncomplications and/or drug interactions or inadequate efficacy of the\nCompany’s product candidates that may limit their development, regulatory\napproval and/or commercialization; the Company’s dependence on third parties\nin connection with product manufacturing, research and preclinical and\nclinical testing; regulatory developments or political changes, including\npolicies related to pricing and pharmaceutical drug reimbursement, in the\nUnited States and foreign countries; the timing and outcome of research,\ndevelopment and regulatory review is uncertain, and Crinetics’ drug\ncandidates may not advance in development or be approved for marketing;\nCrinetics may use its capital resources sooner than expected or our cash burn\nrate may accelerate; any future impacts to our business resulting from\ngeopolitical developments outside our control; and the other risks and\nuncertainties described in the Company’s periodic filings with the\nSecurities and Exchange Commission (SEC). The events and circumstances\nreflected in the company’s forward-looking statements may not be achieved or\noccur and actual results could differ materially from those projected in the\nforward-looking statements. Additional information on risks facing Crinetics\ncan be found under the heading “Risk Factors” in Crinetics’ periodic\nfilings with the SEC, including its annual report on Form 10-K for the year\nended December 31, 2025. You are cautioned not to place undue reliance on\nthese forward-looking statements, which speak only as of the date hereof.\nExcept as required by applicable law, Crinetics does not plan to publicly\nupdate or revise any forward-looking statements contained herein, whether as a\nresult of any new information, future events, changed circumstances or\notherwise.\n\nInvestors:\nGayathri Diwakar\nHead of Investor Relations\ngdiwakar@crinetics.com\n(858) 345-6340\n\nMedia:\nNatalie Badillo\nHead of Corporate Communications\nnbadillo@crinetics.com\n(858) 345-6075\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ff5e7cfa-b9fb-4679-8bf3-6e9d25207b83)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-27T21:13:07.997402508Z","server_sent_at_ms":1777324387997},"received_at":"2026-04-27T21:13:08.059Z","source_url":null},"analysis":{"id":"7432","press_release_id":"9771","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"regulatory","narrative":"Crinetics Pharmaceuticals received European Commission approval for PALSONIFY (paltusotine) for the treatment of acromegaly in adults.\n\nThe approval is based on positive data from two pivotal Phase 3 trials and establishes PALSONIFY as the first once-daily oral therapy for this condition in the European Union.\n\nThe company plans to initiate commercialization efforts in Germany and Austria, with the approval valid in all 27 EU member states and three EEA countries.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Crinetics secures major EC approval, expanding PALSONIFY market to EU and EEA."},"keyFigures":{"drugName":"PALSONIFY (paltusotine)","phaseOfTrial":"Phase 3"},"quotedText":"The European Commission’s decision to approve Palsonify reflects the strength of the clinical data and marks a pivotal step toward bringing this important therapy to even more people living with acromegaly","namedEntities":{"people":[{"name":"Scott Struthers","role":"Founder and Chief Executive Officer"}],"products":["PALSONIFY","paltusotine","atumelnant","CRN09682"],"companies":[{"name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX"},{"name":"European Commission"},{"name":"Sanwa Kagaku Kenkyusho Co., Ltd","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":5,"reasoning":"European Commission approval of the company's lead asset PALSONIFY represents a major binary regulatory event, opening the EU and EEA markets. This is the first regulatory approval for the company outside the U.S."},"tickerRelevance":{"others":[],"primary":"CRNX"},"globalImportance":50,"audienceRelevance":30,"eventTypeSecondary":["product_launch"],"importanceComponents":{"tickerTier":"Mid-Cap Biotech","marketScope":"EU/EEA Expansion","eventGravity":"EC Regulatory Approval"}},"event_type":"regulatory","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":5,"narrative":"Crinetics Pharmaceuticals received European Commission approval for PALSONIFY (paltusotine) for the treatment of acromegaly in adults.\n\nThe approval is based on positive data from two pivotal Phase 3 trials and establishes PALSONIFY as the first once-daily oral therapy for this condition in the European Union.\n\nThe company plans to initiate commercialization efforts in Germany and Austria, with the approval valid in all 27 EU member states and three EEA countries.","key_figures":{"drugName":"PALSONIFY (paltusotine)","phaseOfTrial":"Phase 3"},"named_entities":{"people":[{"name":"Scott Struthers","role":"Founder and Chief Executive Officer"}],"products":["PALSONIFY","paltusotine","atumelnant","CRN09682"],"companies":[{"name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX"},{"name":"European Commission"},{"name":"Sanwa Kagaku Kenkyusho Co., Ltd","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:1fc968c3ac7f7ebb","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-04-27T21:18:11.269Z","global_importance":50,"audience_relevance":30,"importance_components":{"tickerTier":"Mid-Cap Biotech","marketScope":"EU/EEA Expansion","eventGravity":"EC Regulatory Approval"}},"durationMs":95143,"modelName":"glm-4.7"}}